Comparative Evaluation of the Effect of Topical Photodynamic Therapy Versus Topical Calcipotriol on the Clinical and Molecular Characteristics of Oral Leukoplakia: a Randomized Clinical Trial
Trial Snapshot
- Phase
- Phase 3
- Status
- Not yet recruiting
- Sponsor
- Enrollment
- 166
- Locations
- 1
- Primary Endpoint
- Clinical response: Number of patients with Complete response/ Partial response/ No response/ alteration in clinical pattern
Study Overview
Brief Summary
(i)Rationale/ gaps in existing knowledge,: Oral cancer, one of the top three common cancers in India is usually preceded by Oral potentially malignant disorders in nearly two thirds of the cases like Oral leukoplakia. OL has a high prevalence and malignant transformation rates(0.13% - 40.8%). There are no universal protocols for management in OL ranging from preventive, conservative, medical and surgical interventions. They all have limitations and high recurrence rates requiring regular follow up.
(ii)Novelty: Removal of pathological lesions are believed to reduce the risk of malignant transformation in OL. Surgical methods are associated with morbidity and high recurrence rates. Non -invasive methods (like Photodynamic therapy) that can remove the abnormal lesions would be preferred as they are cheaper, convenient, safe with less morbidity and better patient acceptability. They also have the advantage of repeatability with minimum morbidity and damage to adjacent normal tissues. Non -invasive medical management involves topical application of retinoids which are associated with systemic toxicity, recurrence and development of resistance.
(iii)Objectives,
Primary objective:
To compare the effect of 2.5% Toluidine blue mediated topical photodynamic therapy and topical calcipotriol (0.005%) on clinical response after completion of treatment at 4 weeks from baseline during management of Oral leukoplakia
Secondary objectives:
To compare the effect of 2.5% Toluidine blue mediated topical photodynamic therapy with topical Calcipotriol (0.005%) on lesion size, lesion roughness/ whiteness, and oral health quality of life after completion of treatment at 4 weeks and 12 weeks from baseline during management of Oral leukoplakia To compare the effect of 2.5% Toluidine blue mediated topical photodynamic therapy with topical Calcipotriol (0.005%) on salivary molecular markers ( IL6, TNF-α, PCNA, Survivin and VEGF) after completion of treatment at 4 weeks from baseline To compare the adverse events, time to complete response and recurrence rates between the two groups
(iv)Methods,: An open label randomized clinical trial where Group A (n=83) will receive 4 sessions of Toludine blue mediated photodynamic therapy (Fluence 15J/cm2); GroupB (n=83) will receive twice daily tropical application of Calcipotriol (0.005%) over a period of 4 weeks. The clinical response, lesion thickness/ whiteness, lesion size /area, OHIP-14 scores, adverse events and recurrence rates will be compared with baseline at 4 weeks and 12 weeks after completion of therapy. Sterile PVA ophthalmic sponges will be used to evaluate molecular markers ( IL6, TNF-α, PCNA, Survivin VEGF) from treatment site of lesion at baseline and 4 weeks after completion of treatment by ELISA. The data will be analyzed statistically using Intention to treat and as per protocol analysis at significance levels of p<0.05.
(v)Expected outcome.: The study will validate and verify the effectiveness of the TB mediated PDT protocol in the management of OL as compared to other non invasive method of topical Calcipotriol in terms of clinical response ( complete/ partial/ none), lesion thickness/ whiteness, lesion size and it's effect on oral health quality of life. Adverse events if any and recurrence rates or malignant transformation rates will also help in assessment of safety of the protocol. The molecular markers will help to monitor and determine prognosis of the lessons following treatment.
Detailed Description
Objectives
Primary Objectives:
3.1 To compare the effect of 2.5% Toluidine blue mediated topical photodynamic therapy and topical calcipotriol (0.005%) on clinical response after completion of treatment at 4 weeks from baseline during management of Oral leukoplakia
Secondary Objectives:
3.2 To compare the effect of 2.5% Toluidine blue mediated topical photodynamic therapy with topical Calcipotriol (0.005%) on lesion size, lesion roughness/ whiteness, and oral health quality of life after completion of treatment at 4 weeks and 12 weeks from baseline during management of Oral leukoplakia 3.3 To compare the effect of 2.5% Toluidine blue mediated topical photodynamic therapy with topical Calcipotriol (0.005%) on salivary molecular markers ( IL6, TNF-α, PCNA, Survivin and VEGF) after completion of treatment at 4 weeks from baseline 3.4 To compare the adverse events, time to complete response and recurrence rates between the two groups
Study Design
- Study Type
- Interventional
- Allocation
- Randomized
- Intervention Model
- Parallel
- Primary Purpose
- Treatment
- Masking
- None
Masking Description
The outcome assessors for the molecular biomarkers will be masked to the identity of the groups
Eligibility Criteria
- Ages
- 18 Years to 99 Years (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •All diagnosed cases of Oral Leukoplakia with size ≥ 2 cm2 (Van der Waal classification ≥ L2) reporting to the department of OMR, CDER and willing to participate in the study will be included
- •Subjects clinically and histologically diagnosed as Oral Leukoplakia.
- •Subjects > 18 years of age.
- •Subjects willing to participate in the study and to complete the treatment sessions.
Exclusion Criteria
- •History of any topical and/or systemic therapy for Oral Leukoplakia other than general management in last 2 months.
- •Subjects with current or past history of malignancy.
- •Subjects with any lesion suspicious of malignancy requiring biopsy.
- •Subjects with severe dysplasia and carcinoma in situ on biopsy of oral lesion
- •Subjects with history of hyperphotosensitivity (genetic disorders, dermatological conditions, drug induced, systemic conditions)
- •Subjects with calcium, Vit D metabolic and parathyroid disorders
- •Pregnant and lactating females.
Arms & Interventions
Photodynamic therapy
Non-invasive PDT using LED of wavelength ranging from 630-660nm( Fluence 15 J/cm2) as light source and 2.5% TB as photosensitizer will be used in oral leukoplakia once a week for 4 weeks along with preventive and conventional therapy
Intervention: Non-invasive Photo Dynamic Therapy using LED of wavelength ranging from 630-660nm( Fluence 15 J/cm2) as light source and 2.5% TB as photosensitizer (Other)
Photodynamic therapy
Non-invasive PDT using LED of wavelength ranging from 630-660nm( Fluence 15 J/cm2) as light source and 2.5% TB as photosensitizer will be used in oral leukoplakia once a week for 4 weeks along with preventive and conventional therapy
Intervention: Conventional non-invasive management : All subjects in the two groups will receive the same standard conventional non- invasive management advised for OL as per current scientific evidence (Other)
Topical Calcipotriol
Topical application of Calcipotriol ointment 0.005% twice a day for 4 weeks in oral leukoplakia along with preventive and conventional therapy
Intervention: Topical application of Calcipotriol ointment 0.005% twice a day for 4 weeks along with preventive and conventional therapy (Drug)
Topical Calcipotriol
Topical application of Calcipotriol ointment 0.005% twice a day for 4 weeks in oral leukoplakia along with preventive and conventional therapy
Intervention: Conventional non-invasive management : All subjects in the two groups will receive the same standard conventional non- invasive management advised for OL as per current scientific evidence (Other)
Outcomes
Primary Outcomes
Clinical response: Number of patients with Complete response/ Partial response/ No response/ alteration in clinical pattern
Time Frame: Baseline, 4 weeks, 12 weeks
a. Clinical response(Chen et al 2021)(42): 1. complete remission of the lesion clinically evaluated; Complete Response CR 2. partial reduction of at least 20% in the total diameter of the lesion; Partial response PR 3. reduction of the lesion by less than 20% in diameter; No Response NR 4. alteration in the clinical pattern of the lesion (homogeneous and non- homogeneous).
Secondary Outcomes
- Lesion size(Baseline, 4 weeks, 12 weeks)
- Lesion roughness/ whiteness: Number of patients with total resolution/ Moderate resolution/ Minimal change/ No visible change(Baseline, 4 weeks, 12 weeks)
- Oral Health quality of Life: Number of patients with OHIP-14 scores 0-8(baseline, 4 weeks, 12 weeks)
- Concentration of salivary molecular markers ( IL6, TNF-α, PCNA, Survivin and VEGF)(Baseline, 4 weeks)
Investigators
Dr. Shalini Gupta
Professor
All India Institute of Medical Sciences
